MIM
PLX icon

MetLife Investment Management’s Protalix BioTherapeutics PLX Stock Holding History

MetLife Investment Management’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$94.8K Buy
+43,697
New +$108K ﹤0.01% 2565
2023
Q3 		– Sell
-32,363
Closed -$64.7K – 2958
2023
Q2 		$64.7K Buy
+32,363
New +$77.1K ﹤0.01% 2869

Other funds holding PLX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

MetLife Investment Management's PLX Position: Q1 2026 in Review

MetLife Investment Management opened a new position in Protalix BioTherapeutics (PLX) in Q1 2026: 43,697 shares worth $94.8K. The stake represents ﹤0.01% of the portfolio and ranks #2565 among its holdings. This is a return to the name: MetLife Investment Management previously reported a position in PLX as recently as Q2 2023.

MetLife Investment Management first reported a position in PLX in Q2 2023 and has held it in 2 quarters since. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

  • MetLife Investment Management held 43,697 shares of Protalix BioTherapeutics worth $94.8K as of Q1 2026.
  • Protalix BioTherapeutics was a new MetLife Investment Management position in Q1 2026.
  • Protalix BioTherapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q1 2026, its #2565 holding.
  • MetLife Investment Management first reported a position in Protalix BioTherapeutics in Q2 2023 and has held it in 2 quarters since.
  • 99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on MetLife Investment Management's 13F filing for Q1 2026, filed 14 May 2026.